High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. / Harutyunyan, Marina J; Mathiasen, Anders B; Winkel, Per; Gøtze, Jens P; Hansen, Jørgen Fischer; Hildebrandt, Per; Jensen, Gorm Boje; Hilden, Jørgen; Jespersen, Christian M; Kjøller, Erik; Kolmos, Hans J; Gluud, Christian; Kastrup, Jens; CLARICOR Trial Group.

I: Scandinavian Journal of Clinical & Laboratory Investigation, Bind 71, Nr. 1, 01.02.2011, s. 52-62.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Harutyunyan, MJ, Mathiasen, AB, Winkel, P, Gøtze, JP, Hansen, JF, Hildebrandt, P, Jensen, GB, Hilden, J, Jespersen, CM, Kjøller, E, Kolmos, HJ, Gluud, C, Kastrup, J & CLARICOR Trial Group 2011, 'High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial', Scandinavian Journal of Clinical & Laboratory Investigation, bind 71, nr. 1, s. 52-62. https://doi.org/10.3109/00365513.2010.538081, https://doi.org/10.3109/00365513.2010.538081

APA

Harutyunyan, M. J., Mathiasen, A. B., Winkel, P., Gøtze, J. P., Hansen, J. F., Hildebrandt, P., Jensen, G. B., Hilden, J., Jespersen, C. M., Kjøller, E., Kolmos, H. J., Gluud, C., Kastrup, J., & CLARICOR Trial Group (2011). High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Scandinavian Journal of Clinical & Laboratory Investigation, 71(1), 52-62. https://doi.org/10.3109/00365513.2010.538081, https://doi.org/10.3109/00365513.2010.538081

Vancouver

Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P o.a. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Scandinavian Journal of Clinical & Laboratory Investigation. 2011 feb 1;71(1):52-62. https://doi.org/10.3109/00365513.2010.538081, https://doi.org/10.3109/00365513.2010.538081

Author

Harutyunyan, Marina J ; Mathiasen, Anders B ; Winkel, Per ; Gøtze, Jens P ; Hansen, Jørgen Fischer ; Hildebrandt, Per ; Jensen, Gorm Boje ; Hilden, Jørgen ; Jespersen, Christian M ; Kjøller, Erik ; Kolmos, Hans J ; Gluud, Christian ; Kastrup, Jens ; CLARICOR Trial Group. / High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. I: Scandinavian Journal of Clinical & Laboratory Investigation. 2011 ; Bind 71, Nr. 1. s. 52-62.

Bibtex

@article{f91f80d4480048c8b5d03b5f93a7ca5c,
title = "High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial",
abstract = "BACKGROUND: Patients with stable coronary artery disease (CAD) have a poor prognosis. The aim of the study was to evaluate the extent to which serum high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurement alone or together could be prognostic biomarkers in patients with stable CAD.MATERIALS AND METHODS: During the 2.6-year follow-up period 270 patients among the 4264 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 cardiovascular deaths (CVD)).RESULTS: Serum NT-proBNP was significantly associated with MI (hazard ratio (HR), 1. 65 (refers to a 2.72 fold increase in serum level, p = 0.0005), CVD (HR, 2.42, p < 0.0005) and non-CVD (HR, 1.79, p < 0.0005). When correcting for hs-CRP, NT-proBNP was still significantly associated with MI (HR, 1.63, p = 0.0005), CVD (HR, 2.36, p < 0.0005) and non-CVD (HR, 1.66, p < 0.0005). Serum hs-CRP was compared to NT-proBNP less associated with MI (HR, 1.20, p = 0.001), CVD (HR, 1.39, p < 0.0005) and non-CVD (HR, 1.67, p < 0.0005). When corrected for NT-proBNP, hs-CRP was only associated with non-CVD (HR, 1.51, p < 0.0005). When adjusting for cardiovascular risk factors hs-CRP predicted non-CVD (HR, 1.46) and all-cause death (HR, 1.24) and NT-proBNP predicted MI (HR, 1.50), CVD (HR, 1.98), non-CVD (HR, 1.39), and all-cause death (HR, 1.62)(p < 0.0005 for all).CONCLUSION: Increased serum NT-proBNP was a stronger predictor of MI, cardiovascular death and non-cardiovascular death than hs-CRP in patients with stable CAD. Once NT-proBNP was taken into account, hs-CRP did not improve predictions.",
author = "Harutyunyan, {Marina J} and Mathiasen, {Anders B} and Per Winkel and G{\o}tze, {Jens P} and Hansen, {J{\o}rgen Fischer} and Per Hildebrandt and Jensen, {Gorm Boje} and J{\o}rgen Hilden and Jespersen, {Christian M} and Erik Kj{\o}ller and Kolmos, {Hans J} and Christian Gluud and Jens Kastrup and {CLARICOR Trial Group}",
year = "2011",
month = feb,
day = "1",
doi = "10.3109/00365513.2010.538081",
language = "English",
volume = "71",
pages = "52--62",
journal = "Scandinavian Journal of Clinical & Laboratory Investigation",
issn = "0036-5513",
publisher = "Taylor & Francis",
number = "1",

}

RIS

TY - JOUR

T1 - High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial

AU - Harutyunyan, Marina J

AU - Mathiasen, Anders B

AU - Winkel, Per

AU - Gøtze, Jens P

AU - Hansen, Jørgen Fischer

AU - Hildebrandt, Per

AU - Jensen, Gorm Boje

AU - Hilden, Jørgen

AU - Jespersen, Christian M

AU - Kjøller, Erik

AU - Kolmos, Hans J

AU - Gluud, Christian

AU - Kastrup, Jens

AU - CLARICOR Trial Group

PY - 2011/2/1

Y1 - 2011/2/1

N2 - BACKGROUND: Patients with stable coronary artery disease (CAD) have a poor prognosis. The aim of the study was to evaluate the extent to which serum high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurement alone or together could be prognostic biomarkers in patients with stable CAD.MATERIALS AND METHODS: During the 2.6-year follow-up period 270 patients among the 4264 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 cardiovascular deaths (CVD)).RESULTS: Serum NT-proBNP was significantly associated with MI (hazard ratio (HR), 1. 65 (refers to a 2.72 fold increase in serum level, p = 0.0005), CVD (HR, 2.42, p < 0.0005) and non-CVD (HR, 1.79, p < 0.0005). When correcting for hs-CRP, NT-proBNP was still significantly associated with MI (HR, 1.63, p = 0.0005), CVD (HR, 2.36, p < 0.0005) and non-CVD (HR, 1.66, p < 0.0005). Serum hs-CRP was compared to NT-proBNP less associated with MI (HR, 1.20, p = 0.001), CVD (HR, 1.39, p < 0.0005) and non-CVD (HR, 1.67, p < 0.0005). When corrected for NT-proBNP, hs-CRP was only associated with non-CVD (HR, 1.51, p < 0.0005). When adjusting for cardiovascular risk factors hs-CRP predicted non-CVD (HR, 1.46) and all-cause death (HR, 1.24) and NT-proBNP predicted MI (HR, 1.50), CVD (HR, 1.98), non-CVD (HR, 1.39), and all-cause death (HR, 1.62)(p < 0.0005 for all).CONCLUSION: Increased serum NT-proBNP was a stronger predictor of MI, cardiovascular death and non-cardiovascular death than hs-CRP in patients with stable CAD. Once NT-proBNP was taken into account, hs-CRP did not improve predictions.

AB - BACKGROUND: Patients with stable coronary artery disease (CAD) have a poor prognosis. The aim of the study was to evaluate the extent to which serum high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurement alone or together could be prognostic biomarkers in patients with stable CAD.MATERIALS AND METHODS: During the 2.6-year follow-up period 270 patients among the 4264 patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 cardiovascular deaths (CVD)).RESULTS: Serum NT-proBNP was significantly associated with MI (hazard ratio (HR), 1. 65 (refers to a 2.72 fold increase in serum level, p = 0.0005), CVD (HR, 2.42, p < 0.0005) and non-CVD (HR, 1.79, p < 0.0005). When correcting for hs-CRP, NT-proBNP was still significantly associated with MI (HR, 1.63, p = 0.0005), CVD (HR, 2.36, p < 0.0005) and non-CVD (HR, 1.66, p < 0.0005). Serum hs-CRP was compared to NT-proBNP less associated with MI (HR, 1.20, p = 0.001), CVD (HR, 1.39, p < 0.0005) and non-CVD (HR, 1.67, p < 0.0005). When corrected for NT-proBNP, hs-CRP was only associated with non-CVD (HR, 1.51, p < 0.0005). When adjusting for cardiovascular risk factors hs-CRP predicted non-CVD (HR, 1.46) and all-cause death (HR, 1.24) and NT-proBNP predicted MI (HR, 1.50), CVD (HR, 1.98), non-CVD (HR, 1.39), and all-cause death (HR, 1.62)(p < 0.0005 for all).CONCLUSION: Increased serum NT-proBNP was a stronger predictor of MI, cardiovascular death and non-cardiovascular death than hs-CRP in patients with stable CAD. Once NT-proBNP was taken into account, hs-CRP did not improve predictions.

U2 - 10.3109/00365513.2010.538081

DO - 10.3109/00365513.2010.538081

M3 - Journal article

VL - 71

SP - 52

EP - 62

JO - Scandinavian Journal of Clinical & Laboratory Investigation

JF - Scandinavian Journal of Clinical & Laboratory Investigation

SN - 0036-5513

IS - 1

ER -

ID: 33141400